— Know what they know.
Not Investment Advice
Also trades as: XOMAO (NASDAQ) · $vol 0M

XOMAP NASDAQ

XOMA Royalty Corporation
1W: +0.0% 1M: +0.3% 3M: -4.4% YTD: -7.9% 1Y: -0.4% 3Y: +22.3% 5Y: +36.5%
$24.98
+0.00 (+0.00%)
 
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 50 · $301.3M mcap · 12M float · 0.026% daily turnover · Short 57% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$301.3M
52W Range24.93-30
Volume0
Avg Volume3,082
Beta0.86
Dividend$2.16
Analyst Ratings
5 Buy 4 Hold 0 Sell
Consensus Buy
Company Info
CEOOwen Patrick Hughes
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-16
Websitexoma.com
2200 Powell Street
Emeryville, CA 94608
US
510 204 7200
About XOMA Royalty Corporation

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Recent Insider Trades

NameTypeSharesPriceDate
Hughes Owen A-Award 275,000 2024-01-08
Sitko Bradley P-Purchase 250 $13.89 2023-10-03
Sitko Bradley P-Purchase 1,500 $14.25 2023-10-02
Hughes Owen P-Purchase 1,000 $13.83 2023-10-02
Hughes Owen P-Purchase 2,499 $14.43 2023-09-26

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms